<DOC>
	<DOCNO>NCT02670252</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) appear efficient tool cure standard-risk acute lymphocytic leukemia ( ALL ) first CR ( CR1 ) choice BU-based TBI-based conditioning regimen still remain controversial . In study , safety efficacy BUCY TBICY myeloablative conditioning regimens patient undergo allo-HSCT ALL CR1 evaluate .</brief_summary>
	<brief_title>BuCY v TBICY Conditioning Regimen Standard-risk ALL Undergoing Allo-HSCT</brief_title>
	<detailed_description>Allo-HSCT appear efficient tool cure standard-risk ALL CR1 . The condition regimen BUCY TBICY consider standard myeloablative regimen ALL CR1 , choice BU-based TBI-based conditioning regimen still remain controversial.In order analyze impact condition regimen long-term survival relapse , study , safety efficacy BUCY TBICY myeloablative conditioning regimens patient undergo allo-HSCT ALL CR1 evaluate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Standardrisk ALL Achieving CR VILP induction regimen , receive three cycle consolidation therapy With negative MRD pretransplantation Undergoing HLAmatched alloHSCT ( relate unrelated ) Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>